ADMA Biologics





Please Login or Register

Login|Register FREE

Stock Price
Open: 4.47
Prev. Close: 4.49
Low/Hi: 4.47 - 4.60
52-Week: 2.01 - 5.44
Equity: 170,375
90-Day Avg: 158,977
Todays Stock Vol: 32.5
20-Day (HV): 60.7
52-Week (HV): 90.1
Div. Yield:
Earnings: 11-May (Est.)
P/E Ratio:
Market Cap: 203.5 M
Short Int Pct: 0.0%
Pct Held By Inst.: 60.3%
Stock Info
Type: Common
Sector: Healthcare
Industry: Biotechnology

About ADMA

ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease (PIDD) and certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA's lead product candidate, RI-002, has completed a Phase III clinical trial in patients with PIDD and has met the primary endpoint. A BLA for RI-002 was submitted to the FDA on July 31, 2015. The company has received U.S. Patent 9,107,906.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ADMA is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ITOT iShares Core S&P Total U.S. Stock Market ETF 13.4 B 1.33909E+10 3,455 3455 0.0% 0 3 K 3092
IWC iShares Microcap ETF 903.9 M 9.03943E+08 1,371 1371 0.02% 0.0002 166 K 165961
VTI Vanguard Total Stock Market ETF 94.1 B 9.41E+10 3,646 3646 0.0% 0 294 K 293933
VXF Vanguard Extended Market ETF 5.8 B 5.8E+09 3,171 3171 0.0% 0 8 K 8274

Wait, Before You Leave...

Want to Know More About ADMA Earnings?

Receive your FREE email to get Wall Street expected earnings moves and daily upcoming earnings alerts!
Market Chameleon